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 Diabetes is a metabolic disorder that affects over 25 million Americans.  Large 
epidemiological studies have shown that individuals with diabetes are at increased risk of 
many types of cancer, including those often treated with the cardiotoxic anticancer drug 
doxorubicin (DOX).  The combination of diabetes and DOX can cause severe cardiac 
dysfunction, possibly from the adverse effects on cardiac metabolism.  Diabetes leads to 
a shift away from glucose metabolism, while DOX shifts to predominately anaerobic 
glycolysis.  The combination could lead to extremely low levels of ATP.  Exercise has 
the potential to attenuate these adverse metabolic effects by increasing ATP synthesis.  
The purpose of this study was to examine the effect of endurance exercise on the 
combined effects of streptozotocin (STZ) -induced diabetes and DOX on cardiac 
function.  METHODS: Six week old male Sprague Dawley rats were assigned to either 
STZ or placebo injection.  After confirmed diabetes, animals were assigned to either 
treadmill training (TM) or sedentary (SED) groups.  Following the 8 week activity 
period, animals were treated with either 12.5 mg/kg DOX or saline (SAL) injection.  
Cardiac function was measured five days post DOX/SAL injections, using both in vivo 
and ex vivo assessments.  High performance liquid chromatography (HPLC) was used to 
quantify the amount of phosphometabolites (ATP, ADP, AMP, creatine, and 
phosphocreatine) in the left ventricular tissue to access metabolic dysfunction.  
RESULTS:  The STZ groups had significant declines in fractional shortening (FS) and 
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relative wall thickness (RWT), -9% and -31%, respectively, compared to non-diabetic 
groups (p < .05).  Left ventricular developed pressure (LVDP) was significantly increased 
with STZ treatment (16%) and decreased with DOX treatment (-18%).  Exercise 
improved LVDP compared to sedentary animals, although not significantly.  Exercise 
training increased ATP content in STZ treated animals by 27% and 20% in those treated 
with DOX, p < .05.  In addition, exercise training increased Cr levels in STZ and DOX 
treated groups by 62% and 47%, respectively, p<.05. CONCLUSIONS: Exercise 
training provides a protective effect against STZ and DOX-induced cardiac dysfunction.  
In addition, exercise training significantly increased the availability of 
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Over 25 million Americans have diabetes according to the 2011 National 
Diabetes Fact Sheet.  Large epidemiological studies have shown that individuals with 
diabetes are at increased risk of many types of cancer (Vigneri, 2009); in addition, 
diabetic individuals have increased cancer mortality (Suh & Kim, 2011).  The cause of 
this increased cancer mortality in diabetics is not fully understood.  
In 1972 diabetic cardiomyopathy was defined as a cardiac dysfunction in the 
absence of ischemia or valvular dysfunction (Rubler, et al., 1972).  The cause is still 
largely unknown, however, many theories point to alterations in cardiac metabolism.  
Due to a decrease in glucose uptake, along with an increase in circulating fatty acids, 
diabetic metabolism experiences a shift toward predominately fatty acid oxidation 
(Stanley et al., 1999).  In the healthy heart, fatty acid oxidation accounts for 
approximately 60-70% of its total energy production (Neeley & Morgan, 1974).  The 
shift seen in diabetic hearts increases fatty acid oxidation to 90%-100% of its total energy 
production (Lopaschuk, 1996) which has been theorized to lead to cellular and structural 
alterations often described as diabetic cardiomyopathy. 
Doxorubicin (DOX) is an FDA approved chemotherapy agent for the treatment of 
a variety of cancers including non-Hodgkin’s lymphoma, acute leukemia, multiple 
myeloma and cancers of the breast, adrenal cortex, endometrium, lung, and ovary.  
Doxorubicin enters cancerous cells and inhibits DNA, thereby reducing further cellular 
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growth.  The use of DOX is hindered by its adverse effects on the heart.  In fact, 26% of 
patients who received a cumulative dose of 550 mg/m2 experienced congestive heart 
failure (Swain, Whaley, and Ewer, 2003).  Doxorubicin-induced cardiac dysfunction 
presents itself as decreased ejection fraction (Nousiainen, Jantuen, Vanninen, & 
Hartikainen, 2002), increased oxidative stress damage (Minotti, Menna, Salvatorelli, 
Cairo, & Gianni, 2004), and DNA damage (L’Ecuyer et al., 2006).  Theories of DOX-
induced dysfunction include impaired abilities of the mitochondria, sarcoplasmic 
reticulum, and sarcolemma (Pelikan et al., 1989, Zorzato, Salviati, Facchinetti, & Volpe, 
1985, and Boucek et al., 1987); however, research is ongoing in this area and further 
details regarding known mechanisms of cardiotoxicity as well as new mechanisms 
associated with DOX cardiotoxicity continue to be elucidated. 
There are currently no studies that have investigated the effects of DOX treatment 
on cardiac mitochondrial function in a diabetic model.  One study evaluated the 
pharmacokinetics of DOX in diabetic rats and found higher levels of DOX in diabetic 
rats’ serum compared to non-diabetic rats.  Serum creatine phosphokinase activity was 
also significantly higher in diabetic rats compared to non-diabetic rats, suggesting an 
increase in anaerobic metabolism.  The researchers concluded that diabetes may have an 
effect on DOX clearance in cardiac tissue, which exacerbates cardiac dysfunction (Al-
Shabanah, El-Kashef, Badary, Al-Bekairi, & Elmazar, 2000). 
Exercise training has often been used as a protective measure against such adverse 
cardiac effects.  Metabolically, exercise increases both glucose and fatty acid utilization 
and thus increases available ATP.  Several animal models have found that exercise 
training mitigates cardiac dysfunction and reduces apoptotic markers in diabetic animals 
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(Lumini-Olieveia, Magalhaes, Pereira, Moreira, Oliveira, & Ascensao, 2001) and in 
models of DOX cardiotoxicity (Ascensao et al., 2005, Ascensao et al., 2006, Chicco, 
Schneider, & Hayward 2005, Chicco, Hydock, Schneider,& Hayward, 2006). 
Statement of Purpose 
The purpose of this study was three-fold: (1) to examine the combined effects of 
streptozotocin (STZ)-induced diabetes and DOX treatment on cardiac function, (2) to 
investigate the effects of exercise training on the cardiac dysfunction induced by the 
combination of diabetes and DOX, and (3) determine the effects of STZ and DOX on 
cardiac phosphometabolites and the impact exercise may have on this effect.  
Research Hypotheses 
H1 Combined treatment of STZ and DOX will lead to an increase in cardiac 
dysfunction, evidenced by declines in fractional shortening, left 
ventricular developed pressure and rates of pressure development. 
H2 Combined treatment of STZ and DOX will lead to an increase in cardiac 
metabolic dysfunction, evidenced by declines in phosphometabolites in 
left ventricular tissue. 
H3 Endurance exercise training will attenuate the increased cardiac 
dysfunction and metabolic dysfunction associated with the combination of 
STZ and DOX, evidenced by improvements in fractional shortening, left 
ventricular developed pressure, rates of pressure development and 
phosphometabolite availability in left ventricular tissue. 
 
 
Need for the Study 
Diabetes prevalence is increasing every year, and with the recent finding that 
diabetes increases cancer risk and cancer mortality, understanding the effects of 
chemotherapies in the presence of diabetes has never been more important (Vigneri et al., 
2009 and Suh, et al., 2011).  Diabetes alone will increase cardiac dysfunction (Galderisi, 
Anderson, Wilson, and Levy, 1991, Bugger et al., 2010, and Shao et al., 2011) causing 
metabolic shifts and impaired Ca2+ homeostasis (Camps et al., 1992, Oliveria, et al., 2003 
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and Jweied, et al., 2005) which will ultimately lead to decreased ATP production.  
Doxorubicin treatment leads to decreases in all oxidative processes, increasing reliance 
on anaerobic metabolism (Abdel-Aleem et al., 1997 and Gratia et al., 2012).  With 
diabetes, cardiac ATP production comes almost exclusively from fatty acid oxidation, 
while after DOX treatment there is a shift towards cardiac glycolytic metabolism.  At this 
time, the ramifications of the cardiac metabolic effects of these two conditions are 
unclear. 
Cardiac dysfunction caused by both diabetes and DOX have been attenuated with 
the inclusion of exercise training, when assessed individually; however, no study has 
investigated the effects of exercise training on the combined effects of DOX and diabetes 
on cardiac function.  In addition, no studies have investigated the cardiac metabolic 
effects of the combined treatments, DOX and STZ-induced diabetes.  With the 
prevalence of diabetes increasing and the continued use of DOX, this study was an 







ATP - adenosine triphosphate LVDPd - LVDP during diastole 
Ca2+ - calcium LVDs - LV end systolic diameter 
CIT - citrate buffer NADH - nicotinamide adenine dinucleotide 
dehydrogenase
CO - cardiac output PWd - posterior wall thickness during diastole
DNA - deoxyribonucleic acid PWs - posterior wall thickness during systole
DOX – doxorubicin ROS - reactive oxygen species 
dP/dtmax - maximum rate of developed pressure RONS - reactive oxygen and nitrogen species
dP/dtmin - minimum rate of developed pressure RPLC - reversed phase liquid chromatography
EDP - end diastolic pressure RWT - relative wall thickness 
ESP - end systolic pressure SED - sedentary
EF - ejection fraction SOD - superoxide dismutase 
ET - ejection time of aortic blood flow STZ - Streptozotocin
FS - fractional shortening SV - stroke volume
HPLC - high performance liquid chromatography SWd - septal wall thickness during diastole
HR - heart rate SWs - septal wall thickness during systole
i.p. – intraperitoneal TM - treadmill
LV - left ventricular A-Vmax - maximal aortic flow velocity 
LVDd - LV end diastolic diameter M-Vmax - maximal mitral flow velocity
LVDP - LV developed pressure VTI - velocity time integral 








Delimitation of the Study 
 Samples in this study included 5-7 week old male Sprague Dawley rats (150-200 
g).  Diabetes was induced using a 45 mg/kg bolus intraperitoneal (i.p.) injection of STZ.  
The exercise training groups ran on a motorized treadmill five days a week for 8 weeks.  
Cardiotoxicity was induced using a 12.5 mg/kg bolus i.p. injection of DOX, following 
treadmill training. 
Definition of Terms 
Cardiac Efficiency – the ratio of energy output to energy input. 
Cardiomyopathy – disease of the heart when the myocardium becomes enlarged, 
thick, or rigid and can lead to heart failure. 
Cardiotoxocity – damage to the heart from cytotoxic drugs. 
Diabetic Cardiomyopathy – a ventricular dysfunction in diabetes in the absence of 
coronary artery disease and hypertension. 
Diastole – the filling phase in the cardiac cycle. 
Doxorubicin – chemotherapy agent approved by the FDA for the treatment of a 
variety of cancers including non-Hodgkin’s lymphoma, acute leukemia, multiple 
myeloma and cancers of the breast, adrenal cortex, endometrium, lung, and ovary. 
Echocardiogram – a sonogram of the heart used to measure cardiac chamber 
dimensions and blood flow velocities. 
Ejection Fraction – the percentage of blood pumped out of the left ventricular 
with each cardiac cycle. 
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Fractional Shortening – the left ventricular diastolic dimension that is lost during 
systole, reported as a percentage. 
High performance liquid chromatography – an instrument used in analytical 
chemistry to separate compounds in order to identify and quantify the desired compound. 
Systole – the contraction phase of the cardiac cycle. 
Streptozotocin – a chemical toxic to the beta cells of the pancreas.  It is currently 
approved by the FDA for treatment of pancreatic cancer and is commonly used in 









REVIEW OF LITERATURE 
Worldwide, 171 million people have diabetes and that number is expected to rise 
to 366 million by 2030 (Wild, Sigree, Roglic, King, & Green, 2004).  Diabetes is known 
to lead to atherosclerosis in large and coronary arteries, increasing the risk of heart attack 
and stroke (Tarquini, Lazzeri, Pala, Rotella, & Gensini, 2011).  The incidence of cancer is 
also increased in diabetic individuals, with relative risk ranging from 0.81 to 2.51 across 
various cancers (Vigneri et al., 2009).  In addition, cancer mortality is increased among 
the diabetic population compared to the non-diabetic population (Suh & Kim, 2011).  
DOX is one of the most effective chemotherapy drugs used today; however, it is also one 
of the most dangerous.  Doxorubicin-induced cardiomyopathy is so prevalent that 
physicians assess a patient’s risk of heart disease prior to treatment with DOX, and in 
incidences where risk of cardiovascular disease is present, DOX is not used for cancer 
treatment.  Currently, diabetes is not a risk factor evaluated by physicians prior to 
treatment; however, one study found that diabetic patients receiving DOX had an 
increased likelihood of congestive heart failure (Hershman, McBride, Eisenberger, Tasi, 
Grann, & Jacobson, 2008). 
Diabetic Cardiomyopathy 
It is widely believed that cardiac dysfunction in diabetics is the product of 
hypertension and coronary atherosclerosis.  However, large epidemiological studies have 
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shown that the risk of cardiovascular disease remains significantly higher in diabetic 
individuals after controlling for age, blood pressure, weight, cholesterol, and a history of 
coronary artery disease.  Diabetic cardiomyopathy is a clinical term used to describe 
cardiac dysfunction in diabetics in the absence of hypertension and coronary 
atherosclerosis (Aneja, Tang, Bansilal, Garcia, & Farkouh, 2008). 
The cardiac consequences of diabetes include decreased systolic and diastolic 
function accompanied by increases in cardiac mass (Poornima, Parikh, & Shannon, 
2006).  Idiopathic dilated cardiomyopathy is also common.  In fact 75% of those with 
unexplained idiopathic dilated cardiomyopathy were found to have diabetes (Tarquini et 
al., 2011).  As part of the Framingham Heart Study, it was found that diabetic patients 
have increased left ventricular mass, left ventricular end diastolic dimension, left 
ventricular wall thickness and relative wall thickness, and a decrease in fractional 
shortening (Galderisi et al., 1991).  After removing confounding factors such as obesity, 
hypertension, and smoking, left ventricular mass and wall thickness remained 
significantly and independently increased in diabetic patients (Galderisi et al., 1991).  
Diabetic animals present decreased heart rates, fractional shortening and ejection 
fractions (Bidasee, Zheng, Shao, Parbhu, Rozanski, & Patel, 2008), in addition to 
prolonged relaxation times and decreased flow velocity during the filling phase (Shao et 
al., 2011).  Human and animal studies alike have found that diabetes, regardless of cause, 
results in significant alterations to cardiac function. 
Cell death by apoptosis has been shown to increase in diabetic cardiac tissue 
contributing to diabetic cardiomyopathy (Cai, Li Wang, Guo, Jiang, & Kang, 2002, and 
Li et al., 2007).  The mechanisms are unknown; however, two developing theories 
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involve mitochondrial and endoplasmic reticulum dysfunction and oxidative stress 
activating apoptotic pathways leading to cell death.  Dysfunction of the mitochondria and 
endoplasmic reticulum, and an increase in oxidative stress will be discussed below in 
greater detail. 
Diabetes-Induced Metabolic Dysfunction 
Considerable changes occur in diabetic energy metabolism which often precede 
cardiac contractile dysfunction.  In the diabetic heart, there is an increase in fatty acid 
circulation and oxidation, accompanied by low levels of glucose utilization (Stanley, 
Lopaschuk, and McCormack, 1997).  In various studies, STZ-induced type-1 diabetes has 
resulted in decreased cardiac function, cardiac efficiency, mitochondrial function, and 
calcium handling, with increases in oxidative stress (Bugger et al., 2010, Shao et al., 
2011). 
Glucose Metabolism 
Myocardial glucose transport, glycolysis, and glucose oxidation are all decreased 
in diabetic tissues.  Myocardial glucose transport has been shown to be defective in both 
diabetic humans and STZ-induced diabetic animals (Stanley et al., 1999).  Glucose 
transporters, GLUT 1 and 4, are downregulated with diabetes (Camps et al., 1992).  
Decreased glycolysis is accompanied by an increase of intracellular glucose 6-phosphate 
and a decrease in the fructose 1,6-biphosphate/fructose 6-phosphate ratio.  
Phosphofructokinase (PFK) is a key enzyme in glycolysis that catalyzes the conversion of 
fructose 6-phosphate to fructose 1,6-bisphosphate.  With the increase in fatty acid 
oxidation, there is an increase in citrate, which, along with high ATP/ADP ratios, will 
inhibit PFK activity and thus inhibit glycolysis further.  The rate of glucose oxidation is 
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also significantly reduced in cardiac tissue due to decreased pyruvate dehydrogenase 
(PDH) activity (Wall & Lopaschuk, 1989).  Pyruvate dehydrogenase is inhibited by high 
plasma levels of free fatty acid and an increase in fatty acid oxidation.  The condition of 
increased blood glucose, hyperglycemia, can itself lead to cardiac tissue injury.  
Hyperglycemia increases the production of reactive oxygen species (ROS) and nitric 
oxide synthase (NOS), leading to an increase in cytochrome c-mediated caspase 3 
activation, which activates pro-apoptotic pathways (Cai, et al., 2002).  
Fatty Acid Metabolism 
Fatty acid oxidation typically provides 60 – 70% of the heart’s energy needs 
(Neeley & Morgan, 1974); however, in the uncontrolled diabetic heart, that percentage 
raises to 90 – 100% (Lopaschuk, 1996).  Decreased glucose uptake and glucose 
metabolism, discussed previously, are only a part of the puzzle.  Increases in plasma 
concentration of fatty acids, fatty acid transporters, and fatty acid uptake appear to be 
large components in the shift to increased fatty acid utilization.  Studies using isolated 
working heart models have shown that significant metabolic alterations occur within the 
cardiac mitochondria.  By perfusing hearts with buffer absent of fatty acids, studies have 
found that the diabetic heart only utilizes glucose for 20% of its energy requirements 
(Lopachuk, 1996).  Carnitine palmitoyl-transferase 1 (CPT 1) appears to play a 
significant role in fatty acid metabolism in the diabetic heart.  CPT 1 is a key enzyme in 
the transport of fatty acids from the cytoplasm into the mitochondria facilitating the 
transfer of fatty acyl CoA into fatty acylcarnitine, and its activity is inhibited by malonyl 
CoA.  The concentration of malonyl CoA is decreased in the STZ diabetic heart due to 
decreases in acetyl CoA carboxylase (ACC) (Sakamoto, Barr, Kavanagh, & Lopaschuk, 
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2000).  ACC catalyzes the conversion of acetyl CoA into malonyl CoA.  In addition, ‘5 
AMP activated protein kinase activity, a known inhibitor of ACC, is increased in STZ 
diabetic animals.   
Cardiac efficiency, the ratio of energy output (pressure: volume area) to energy 
input (oxygen consumption), is also decreased in STZ treated diabetic animals (How, 
Aasum, Severson, Chan, Essop, & Larsen, 2006).  The shift to fatty acid metabolism 
leads to increased oxygen demands that outweigh ATP production.  One study found that 
although ATP synthesis is slowed in diabetic animals, the decline in production is not 
significantly affected (Ferko, M., Gvozdjakova, A., Kucharska, J., Mujkosova, J., 
Waczulikova, I., Styk, J., et al., 2006).  An overview of diabetic metabolism can be seen 





Figure 1: Diabetic metabolism. A shift from glucose metabolism to fatty acid metabolism 
can be seen by the increase in CPT 1 activity, which increases the transport of fatty acids 
into the mitochondrial matrix. In addition, AMPK is increased and ACC is decreased 
leading to a decreased inhibition of CPT 1 by malonyl CoA. PFK and PDH are also 
decreased, slowing both glycolysis and glucose oxidation. 
 






































An increased production of free radicals in heart tissue has been linked to diabetic 
cardiac complications (Jay, Hitomi, & Griendling, 2006).  Evidence suggests increased 
ROS production is not only found in diabetic cardiac mitochondria, but also cytosolic 
ROS production is present with hyperglycemia (Jay et al., 2006).  Reactive oxygen 
species, with its short half-life, typically inflicts its damage close to its origin or, in this 
case, the mitochondria.  With further insults on the mitochondria, ROS production is 
exacerbated.  Studies have found that treatment with ROS scavengers (e.g., 
metallonthionin, catalase and manganese superoxide dismutase) reversed diabetic 
cardiomyopathy (Liang, Carlson, Donthi, Kralik, Shen, & Epstein, 2002, Matsushima, et 
al., 2006, Shen, Zheng, Metreveli, & Epstein, 2006). 
Calcium Handling 
Calcium handling is another theory surrounding altered cardiac function seen in 
patients with diabetes.  Glycolysis typically occurs close to the sarcoplasmic reticulum 
(SR) and sarcolemma because that is where the necessary enzymes can be found, 
additionally, ion transporters (such as SERCA2a and Na/K ATPase) located on the SR 
and the sarcolemma are preferentially fueled by ATP generated from glycolysis (Hattori 
et al., 2000, Kashihara, Shi, Yu, McNeill, & Tibbits, 2000).  If due to decreased ATP, 
SERCA2a and Na/K ATPase transporters’ activity will be decreased and Ca2+ 
homeostasis will be impaired.  As a result of impaired Ca2+ homeostasis, myofilament 
contractile function is abated and could lead to the development of cardiomyopathies 
(Jweied, et al., 2005 and An & Rodrigues, 2006).  When a mitochondrial permeability 
transition pore inhibitor (cylcosporin) was introduced to the STZ diabetic rat, differences 
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in calcium handling were not observed.  Thus, confirming that calcium handling is 
impaired in diabetic cardomyocytes, which may possibly result in compromised energy 
production and reduced myofilament contractility (Oliveria, et al., 2003). 
Doxorubicin-Induced Cardiac Dysfunction 
 Doxorubicin is one of the most prescribed chemotherapies today.  It is an 
anthracycline anticancer treatment used to treat non-Hodgkin’s lymphoma, acute 
leukemias, multiple myeloma and cancers of the breast, adrenal cortex, endometrium, 
lung, and ovary since the 1960s.  However its use is strongly regulated due to its harmful 
effects on the cardiovascular system.  Doxorubicin’s mechanism of action is still being 
studied, but it is believed to preferentially enter cells that are metabolically active.  Upon 
entering, it binds to nuclear DNA and interacts with DNA strands by intercalation.  
Doxorubicin also inhibits topoisomerase II activity preventing replication and further 
growth of the tumor.  
Despite its potent anticancer effects, DOX’s cardiotoxic effects have hindered its 
clinical usage.  In human studies, patients who receive DOX have a decreased ejection 
fraction and diastolic dysfunction.  In animals, DOX treatment decreases left ventricular 
developed pressure as well as ejection fraction, fractional shortening and +dP/dt and 
increases diastolic pressure and –dP/dt.  
Wu and colleagues (2002) investigated the in vivo and in vitro apoptosis of 
cardiomyocytes and endothelial cells in cardiomyopathy induced by DOX.  Male rats 
were injected with 4 mg/kg three times per week for two weeks and sacrificed six weeks 
following the last treatment.  DNA laddering, TUNEL assay and caspase 3 expression 
assays were performed on the cardiomyocytes and endothelial cells of the rats.  The in 
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vitro study cultured cardiomyocytes from 3-5 day old rats and endothelial cells from 
human umbilical veins and treated them with DOX.  Analysis on these cells included: 
apoptosis measures and expressions of Fas antigen, Bax, Bcl-2 and caspase-3.  The in 
vivo study resulted in increased apoptosis and increased expression of caspase-3 in both 
cardiomyocytes and endothelial cells compared to controls.  The in vitro study showed an 
increase in apoptotic cells, Fas, Bax, capase-3 and a decrease in Bcl-2.  The researchers 
concluded that apoptosis induced by DOX can occur both in vivo and in vitro in 
cardiomyocytes and endothelial cells. 
Doxorubicin-Induced Metabolic Dysfunction 
Glucose Metabolism 
 Little is understood about the DOX effects on glucose metabolism.  One study 
found that glucose uptake markedly increased with DOX treatment; however, the effect 
was transient and within three hours, cardiomyocytes showed a marked decrease in 
glucose uptake (Hrelia et al., 2002).  Jeyaseelan and colleagues (1997) saw a decrease in 
mRNA levels of the key glycolytic enzyme PFK.  One research group found that all 
oxidative processes, including glucose oxidation, were decreased with high levels of 
DOX (Abdel-Aleem et al., 1997).  In addition, decreased activities of both PDH and 
lactate dehydrogenase (LDH) accompanied DOX treatment, concluding that in addition 
to glucose, lactate and pyruvate oxidation is reduced in DOX treated cardiomyocytes 
(Gratia et al., 2012). 
Fatty Acid Metabolism 
Just as with glucose metabolism, there is conflicting evidence regarding the effect 
of DOX on fatty acid metabolism.  In heart failure, there is a decrease in fatty acid 
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oxidation and an increase in glucose utilization as a compensatory measure.  
Cardiotoxicity induced by DOX has been associated with decreases in both glucose and 
fatty acid utilization.  Wakasugi and colleagues (1993) found that although both glucose 
and fatty acid metabolism were significantly decreased, fatty acid oxidation was 
decreased to a lesser extent.  CPT 1, as discussed above, is a key enzyme in the 
transportation of fatty acids and was found to be impaired in DOX treated 
cardiomyocytes, which would also lead to decreased fatty acid oxidation (Abdel-Aleem 
et al., 1997).  Doxorubicin-induced cardiotoxicity leads to a significant decrease in 
myocardial ATP, along with decreases in creatine, phosphocreatine and lactate, 
indicating both aerobic and anaerobic metabolic dysfunction (Wallace, 2003).  Fatty acid 
oxidation was inhibited following DOX administration and compensated for by an 
increase in aerobic glycolysis with contributions from lactate and pyruvate, which is 
contrary to Wallace, who, as stated above, found lactate oxidation to be decreased 
(Carvalho, et al., 2010).   
Oxidative Stress 
The quinone structure of DOX makes it prone to a one electron reduction forming 
a semiquinone (Zucchi & Danesi, 2003).  This reduction is catalyzed by the exogenous 
NADH dehydrogenase in the cardiac mitochondria (Nohl, Gile, & Staniek, 1998).  The 
semiquinone then donates an electron to oxygen, forming a superoxide anion (Olson & 
Muslin, 1990).  The superoxide anion can either trigger lipid peroxidation or be 
converted to hydrogen peroxide (Olson et al., 1990).  Mimnaugh, Trush, Bhatnager and 
Gram (1985) found that lipid peroxidation increased 4-fold after treatment with DOX.  
Free radicals can also be formed from the interaction of DOX and iron (Minotti, Cairo, & 
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Monti, 1999).  The interaction passes electrons between iron, DOX and oxygen with a 
final product of one iron (III)-DOX (aldehyde) and two superoxide anions (Olson et al., 
1990).  Voltage-dependent anion channels release cytochrome c, resulting in the 
activation of caspase-3 and apoptosis (Childs, Phaneuf, Dirks, Phillips, and 
Leeuwenburgh, 2002). 
Clark and colleagues (2002) found that after treatment with DOX, cells showed 
an increase in Akt activation after hydrogen peroxide-induced oxidative stress.  Free 
radicals impact cardiac function through its effects on the SR.  Free radicals lead to 
release and depletion of calcium from the SR resulting in impaired cardiac contractility 
and relaxation (Carafoli, 1985).  Free radicals may also affect cardiac mitochondria.  
After administration of DOX to isolated mitochondria, superoxide production rose 
leading to an increase in cytochrome c efflux (Green & Leeuwenberg, 2002). 
Cytochrome c activates caspase-3 which begins the apoptotic pathway, as discussed 
above. 
Calcium Handling 
Doxorubicin is hypothesized to increase intracellular levels of calcium.  One 
mechanism is through the altering of the sarcolemmal Na/K-ATPase channels and the 
Na/Ca exchanger (Boucek et al., 1987).  Another mechanism involves the sarcoplasmic 
reticulum (SR). It is theorized that DOX can alter the release of calcium from the SR, 
depleting its stores (Zorzato et al., 1985).  Solem, Henry and Wallace (1994) found that 
DOX leads to calcium cycling in the mitochondria and depolarization of the sarcolemma 
and this effect could be inhibited by cyclosporine A (a known inhibitor of mitochondrial 
permeability transition pores) or ruthenium red (a mitochondrial Ca2+ uniporter inhibitor).  
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A later study by Solem, Heller and Wallace (1996) found a dose-dependent sensitivity to 
calcium-induced calcium release and membrane depolarization which induced cellular 
apoptosis in cardiac mitochondria.  
Combined Effects of Diabetes and Doxorubicin 
 One study conducted by Al-Shabanah and colleagues (2000) investigated the 
combined effects of STZ and DOX.  Animals were injected with 65 mg/kg of STZ, and 
two weeks after diabetes was induced, animals were injected with 15 mg/kg of DOX.  
Blood samples were collected and the animals were sacrificed 24 hours following the 
DOX injection.  Streptozotocin-induced diabetic rats, whether treated with DOX or 
saline, had significantly decreased body weight, heart weight, serum glucose and urine 
volume, while DOX alone only showed significant decreases in body weight.  Serum 
DOX levels were also measured at seven different time points following the DOX 
injection.  Serum DOX levels in diabetic animals were more than 30% higher than non-
diabetic animals.  Serum creatine phosphokinase activity was also significantly higher in 
STZ diabetic rats treated with DOX compared to non-diabetic treated with DOX, 
signifying an altered metabolic state with combined treatment.  The researchers 
concluded that the pharmacokinetics of DOX is significantly altered in STZ diabetic 
animals, significantly decreasing the clearance of DOX. 
Exercise Training 
Exercise training is known to provide cardioprotective effects.  Exercise leads to 
cardiac hypertrophy and increased ejection fraction.  Metabolically, exercise increases 
both glucose and fatty acid utilization and thus increases available ATP.  Exercise leads 
to an increase in AMPK, which in turn inactivates ACC and malonyl CoA, thereby 
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increasing fatty acid oxidation.  AMPK also stimulates glucose uptake (through insulin, 
which may not be present in STZ diabetic hearts) and glycolysis by activating PFK.  Thus 
both glucose and fatty acid utilization are increased; however, in the DOX heart 
cardiomyopathies are often present.  In the presence of cardiomyopathies, the heart may 
be in a state of compensated heart failure, in which it is predominately anaerobic due to 
its ischemic state. 
Exercise Training in Diabetic Models 
A study conducted by Bidasee and colleagues (2008) has tested the effects of 
exercise training on cardiac function of STZ-induced diabetic rats.  It was found that 
following seven weeks of diabetes, rats had decreased heart rates, fractional shortening, 
and ejection fraction.  Three weeks of treadmill training was able to improve ejection 
fraction.  A similar study using STZ-induced diabetic rats found that after nine weeks of 
treadmill training and 7 weeks of STZ-induced diabetes exercise was found to 
significantly attenuate the magnitude of mitochondrial ultrastructure damage, assessed 
using transmission electron microscopy (Searls, Smirnova, Fegley, & Stehno-Bittel, 
2004).  No study has measured the combined effect of exercise and diabetes on cardiac 
ATP content. 
Exercise Training with Doxorubicin  
Treatment 
 
The use of exercise to attenuate DOX-induced cardiotoxicity has been 
demonstrated across different modes of exercise, intensities, and durations (Ascensao et 
al., 2005, Chicco, Schneider, & Hayward, 2005, Chicco et al., 2006 and Wonders, 
Hydock, Schneider, & Hayward, 2008).  All have positively identified exercise as a 
means of attenuating cardiotoxicity through increased cardiac function, decreased pro-
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apoptotic factors, decreased oxidative stress damage, increased antioxidant capacity, and 
improved calcium homeostasis (Ascensao et al. 2005, Ascensao et al., 2006, Chicco, et 
al., 2005, Chicco et al., 2006, Hydock, Lien, Jensen, Schneider, & Hayward, 2011, and 
Wonders, Hydock, Greufe, Schneider, & Hayward, 2009).  Although numerous studies 
have researched the metabolic effects of exercise in DOX treated hearts, no studies have 
quantified cardiac ATP content as a means of understanding the metabolic effects.  
Conclusion 
Diabetes has been connected to cancer risk and cancer mortality (Vigneri et al., 
2009 and Suh, et al., 2011).  Human studies have found increased left ventricular mass, 
left ventricular end diastolic dimension, left ventricular wall thickness and relative wall 
thickness and a decrease in fractional shortening in diabetic patients (Galderisi et al., 
1991).  Animal studies with STZ-induced diabetes have also resulted in adverse effects 
such as, decreased cardiac function, cardiac efficiency, mitochondrial function, calcium 
handling and increased oxidative stress damage (Bugger et al., 2010, Shao et al., 2011).  
Oxidative stress is increased with diabetes both in the mitochondria and cytosol leading 
to increased cardiac damage (Jay et al., 2006).  Further decrements in cardiac function, as 
well as decreased energy production and contractility can occur from impaired Ca2+ 
homeostasis (Oliveria, et al., 2003 and Jweied, et al., 2005).  The shift to fatty acid 
oxidation is due to decreased glucose transporter and increase fatty acid circulation 
(Camps et al., 1992).  Relying on fatty acids almost entirely for ATP production will lead 
to a significant decrease in cardiac efficiency due to increased oxygen demand (How et 
al., 2006).   
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Doxorubicin treatment leads to decreases in all oxidative processes: fatty acid, 
glucose, lactate and pyruvate (Abdel-Aleem et al., 1997 and Gratia et al., 2012).  With 
both aerobic and anaerobic metabolic dysfunction and increased percentage of energy 
production coming from anaerobic pathways, DOX treatments result in significant 
decreases in ATP production (Wallace, 2003 and Kawasaki, Lee, Shimizu, Ishii, and 
Ueda, 1996).  With the DOX-treated heart preferential to anaerobic metabolism and the 
diabetic heart being fueled almost entirely by fatty acid oxidation, the combination of a 
diabetic patient receiving DOX treatments could be detrimental to the heart’s ability to 
generate ATP for contraction and relaxation. 
Our lab has successfully attenuated the cardiotoxic effects of DOX treatment with 
exercise training.  Cardiac dysfunction by diabetes has also been attenuated with the 
inclusion of exercise training.  No study has looked at the effects of exercise training on 
the combined effects of DOX and diabetes on cardiac function.  In addition, no study has 
looked at the cardiac metabolic effects of combined treatments with DOX and STZ-
induced diabetes.  Exercise has been shown to attenuate the effects of the treatments 
alone, however, the combination of DOX and STZ may lead to the increase of other 
substrates (other than glucose and fatty acids) or it may increase the ATP debt.  With the 
prevalence of diabetes increasing and the continued use of DOX, this study provides 
much needed knowledge about the combined effects of these conditions on the heart and 
the potential role of exercise in alleviating those effects. 









 The purpose of this study was to assess the cardiovascular effect of endurance 
training in type-1 induced diabetic animals treated with DOX.  This was accomplished by 
first inducing diabetes with STZ.  Animals were randomly assigned to either STZ or 
citrate buffer only (CIT) groups.  Three days following STZ/CIT injection, diabetes was 
confirmed via blood glucose testing.  Animals then were randomly assigned to either 
sedentary (SED) or treadmill trained (EX) groups.  Twenty-four hours following the last 
treadmill session animals were again randomly assigned to either SAL or DOX groups.  
Five days following SAL/DOX injections animals were sacrificed.  Cardiac function was 
assessed using an isolated working heart model and mitochondrial function was assessed 
by quantifying phosphometabolites (ATP, ADP, AMP, creatine, and creatine phosphate) 
using HPLC.  Figure 2 displays the experimental design, and the following sections 











Figure 2: Proposed Study Design 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. 
 
Subjects 
 This study used 108 male Sprague-Dawley rats (150-200g) obtained from Harlan 
Industries (Indianapolis, IN).  Rats were housed two per cage and given free access to 
standard rat chow and distilled water ad libtium.  Animals were kept in a temperature 
controlled facility and kept on a 12:12 hour light-dark cycle.  All of the proposed 
procedures have been approved by the University of Northern Colorado Institutional 
Animal Care and Use Committee (IACUC) and were in compliance with the Animal 






Male Sprague-Dawley rats weighing 150-200g were chosen because they have 
been shown to rarely develop ketosis following STZ-induced type I diabetes.  
Streptozotocin was used to induce type I diabetes with an i.p. injection of 45 mg/kg in a 
0.01 M citrate buffer at a pH of 4.5, the injection was prepared immediately prior to 
injection.  Control animals received citrate buffer only.  Animals were fasted 6-8 hours 
prior to STZ injection and given free access to food for the remainder of the study.  There 
is a high risk of death immediately following STZ injection due to the rapid release of 
insulin from necrotic islet β-cells causing life threatening hypoglycemia.  To combat this, 
forty-eight hours following STZ injection animals were given free access to 10% sucrose 
water.  Non-fasting blood glucose was tested 3 days post STZ injection to confirm the 
presence of diabetes.  A blood glucose value >250 ml/dL was used to confirm the 
diabetic condition.  Animals with lower blood glucose (<250ml/dL) were excluded from 
the experiment (Bidasee et al., 2008). 
Blood glucose, body weight and food intake were measured weekly.  Blood 
glucose was measured with an Accu Chek blood glucose meter.  The tail was first 
cleaned with ethanol, and a lancet was used to stick the tip of the tail.  The tail was then 
milked until at least 0.6 microliters of blood was absorbed into the testing strip (Bidasee 
et al., 2008).  In the cases where blood glucose exceeds 600 ml/dL the test was performed 
a second time. If blood glucose tests higher than 600 mg/dL on the second test, the 






Animals in STZ and SAL groups were further divided into the following groups; 
CIT+SED, CIT+EX, STZ+SED, and STZ+EX.  Animals in SED groups were restricted 
to cage activity for 8 weeks.  Animals in EX groups were trained five days a week 
(Monday – Friday) for 8 weeks during their dark cycle.  Training speed was held constant 
at 18 m/min for the 8 week training schedule.  Exercise training progressed to a 
maximum of 15% incline for 60 minutes at the end of the training period.  A summary of 
the proposed exercise training regimen appears in Table 2.  
 
Table 2: Exercise Training Protocol 
Week 1 2 3 4 5 6 7 8 
Speed (m/min) 18 18 18 18 18 18 18 18 
Incline (%) 0 0 0 3 6 9 12 15 
Duration (min) 20 40 60 60 60 60 60 60 
 
Doxorubicin Injection 
Twenty-four hours following the last exercise training session, animals in the 4 
groups were further divided into DOX and SAL for a total of 8 groups (CIT+SED+SAL, 
CIT+SED+DOX, CIT+EX+SAL, CIT+EX+DOX, STZ+SED+SAL, STZ+SED+DOX, 
STZ+EX+SAL, and STZ+TM+DOX).  DOX was administered as a bolus i.p. injection at 
a dose of 12.5 mg/kg. Five days post DOX/SAL injection, animals were sacrificed and 
cardiac function was assessed using an isolated perfused working heart model. 
Echocardiography 
In vivo cardiac function was assessed using echocardiography on sedated rats with 
a commercially available echocardiographic system (Toshiba Nemio 30; 10 MHz 
transducer).  Animals were sedated with ketamine (40 mg/kg, i.p.), and echocardiography 
was completed within 10-15 minutes after the administration of the sedative.  From the 
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short-axis view, an M-mode tracing of the LV was obtained for measures of septal wall 
thickness during systole (SWs) and diastole (SWd), posterior wall thickness during 
systole (PWs) and diastole (PWd), LV end systolic diameter (LVDs), and LV end 
diastolic diameter (LVDd).  Aortic flow was assessed from the five-chamber apical view 
and mitral flow with a four-chamber apical view with the smallest possible sample 
volume placed at the tips of the valve.  LV mass was calculated as 1.04[(LVDd + PWd + 
SWd)3 – LVDd3], relative wall thickness (RWT) was calculated as (PWd + SWd)/LVDd, 
and fractional shortening (FS) was calculated as (LVDd – LVDs)/LVDd. 
Isolated Perfused Working Heart 
Following echocardiography, animals were administered heparinized sodium 
pentobarbital (i.p., 50 mg/kg).  Anesthesia was confirmed by the absence of a tail pinch 
reflex, at which time the heart was rapidly excised and immersed in ice-cold Krebs 
Henseilit buffer (120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl, 25 mM 
NaHCO3, 17 mM glucose, and 0.5 mM EDTA).  The aorta was cannulated within one 
minute, and the heart was subjected to retrograde perfusion with Krebs-Henseilit buffer 
saturated with 95% O2/5% CO2. Temperature was maintained in a water-jacketed column 
at 37°C for the duration of the experiment.  The pulmonary vein was then cannulated and 
flow was re-directed to enter through the left atrium and exit through the aorta to measure 
cardiac function using the working heart method.  The heart was then given 15 minutes to 
equilibrate before data were collected.  Preload and afterload was set at 10 cmH20 and 





Quantification of Cardiac Phosphometabolites 
Following isolated heart experiments, the left ventricle was isolated, frozen in 
liquid nitrogen, and stored at -80°C for the subsequent measurement of ATP, ADP, AMP, 
phosphocreatine, and creatine using high performance liquid chromatography (HPLC).  
Frozen ventricular samples were weighed and homogenized immediately with 500 µL 
cold (4°C) perchloric acid (7%).  The homogenate was centrifuged at 8,800g in an 
eppendorf centrifuge for 5 minutes.  The supernatant was extracted and the pH adjusted 
to 7.0 with potassium hydroxide and centrifuged again at 8,800g for 5 minutes.  The 
supernatant was removed and filtered, and the pellet was discarded.  Once filtered, the 
sample (filtered supernatant) was injected into a reversed phase C-18 column, 15 cm in 
length with a 2µm particle size.  An isocratic mobile phase was used to measure 
quantities of ATP, ADP, AMP, Cr, and PCr.  The running buffer during the isocratic 
mobile phase consisted of 215 mM Kh2PO4, 2.3 mM TBAHS, 3.5% acetonitrile, pH to 
6.25 with KOH and filtered through a 2 µm cellulose acetate filter. The 
spectrophotometer was set at 204 nm with a flow rate of 0.25 ml/min.  All 
phosphometabolites (ATP, ADP, AMP, phosphocreatine, and creatine) eluted from the 
column within 10 minutes.  Retention times are located in Table 3. 
Table 3: HPLC Phosphometabolite Retention Times 












Three-Factor Analysis of Variance was used to determine factor effects and 
interaction effects of the three treatments, citrate buffer/STZ, sedentary/treadmill training, 
and saline/DOX. If a significant F-value was observed, a Tukey post-hoc pairwise 
comparisons were used to determine which groups were significant.  A family alpha level 









Over 25 million Americans have diabetes according to the Centers for Disease 
Control and Prevention.  Large epidemiological studies have shown that individuals with 
diabetes are at increased risk of many types of cancer (Vigneri, 2009) along with 
increased cancer mortality (Suh & Kim, 2011).  The cause of this increased cancer 
mortality in diabetics is not fully understood.  
Diabetic cardiomyopathy is defined as a cardiac dysfunction in the absence of 
ischemia or valvular dysfunction (Rubler, et al., 1972).  The cause is still largely 
unknown, however, many theories point to alterations in cardiac metabolism.  Decreased 
glucose uptake, along with increased circulating fatty acids causes the diabetic individual 
to experience a shift toward predominately fatty acid oxidation (Stanley et al., 1999).  In 
the healthy heart, fatty acid oxidation accounts for approximately 60-70% of total cardiac 
energy production (Neeley & Morgan, 1974).  The shift seen in diabetic hearts increases 
fatty acid oxidation to 90%-100% of its total energy production (Lopaschuk, 1996) which 
may lead to cellular and structural alterations often described as diabetic cardiomyopathy. 
Doxorubicin (DOX) is an FDA approved chemotherapy agent for the treatment of 
a variety of cancers including non-Hodgkin’s lymphoma, acute leukemia, multiple 
myeloma and cancers of the breast, adrenal cortex, endometrium, lung, and ovary.  
Doxorubicin enters cancerous cells and inhibits DNA function, thereby reducing further 
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cellular growth.  The use of DOX is hindered by its adverse effects on the heart.  In fact, 
26% of patients who received a cumulative dose of 550 mg/m2 experienced congestive 
heart failure as a result (Swain, Whaley, and Ewer, 2003).  Doxorubicin-induced cardiac 
dysfunction presents as decreased ejection fraction (Nousiainen, Jantuen, Vanninen, & 
Hartikainen, 2002), increased oxidative stress (Minotti, Menna, Salvatorelli, Cairo, & 
Gianni, 2004), and DNA damage (L’Ecuyer et al., 2006).  Theories of DOX-induced 
dysfunction include impaired abilities of the mitochondria, sarcoplasmic reticulum, and 
sarcolemma (Pelikan et al., 1989, Zorzato, Salviati, Facchinetti, & Volpe, 1985, and 
Boucek et al., 1987); however, research is ongoing in this area and further details 
regarding known mechanisms of cardiotoxicity as well as new mechanisms associated 
with DOX cardiotoxicity continue to be elucidated. 
Exercise training has often been used as a protective measure against such adverse 
cardiac effects.  Metabolically, exercise increases both glucose and fatty acid utilization 
and thus increases available ATP.  Several animal models have studied this effect with 
great success and have found that exercise training mitigates cardiac dysfunction and 
mitigates cardiac injury in diabetic animals (Lumini-Olieveia, Magalhaes, Pereira, 
Moreira, Oliveira, & Ascensao, 2001) and in models of DOX cardiotoxicity (Ascensao et 
al., 2005, Ascensao et al., 2006, Chicco, Schneider, & Hayward 2005, Chicco, Hydock, 
Schneider,& Hayward, 2006). 
The purpose of this study was to examine the combined effects of streptozotocin 
(STZ)-induced diabetes and DOX treatment on cardiac function, phosphometabolite 
levels and the effects of exercise training on the cardiac and metabolite dysfunction 





 A total of 108 male Sprague-Dawley rats (150-200g) were obtained from Harlan 
Industries (Indianapolis, IN).  Rats were housed two per cage and given free access to 
standard rat chow and distilled water ad libtium.  Animals were kept in a temperature 
controlled facility and kept on a 12:12 hour light-dark cycle.  All of the proposed 
procedures were approved by the University of Northern Colorado Institutional Animal 
Care and Use Committee (IACUC) and are in compliance with the Animal Welfare Act 
guidelines. 
Streptozotocin-Induced Diabetes 
Streptozotocin (STZ) was used to induce type I diabetes in the STZ group with an 
i.p. injection of 45 mg/kg in a 0.01 M citrate buffer at a pH of 4.5.  Control animals (CIT) 
received an equivalent volume citrate buffer as a control.  Animals were fasted 6-8 hours 
prior to STZ injection and given free access to food for the remainder of the study.  There 
is a high risk of death immediately following STZ injection due to the rapid release of 
insulin from necrotic islet β-cells causing life threatening hypoglycemia.  To combat this, 
forty-eight hours following STZ injection animals were given free access to 10% sucrose 
water.  Non-fasting blood glucose was tested 3 days post STZ injection to confirm the 
presence of diabetes and a blood glucose value >250 ml/dL was used to confirm the 
diabetic condition (Bidasee et al., 2008).  Animals with blood glucose values <250ml/dL 
were excluded from the study. 
Blood glucose, body weight and food intake were measured weekly.  Blood 
glucose was measured with an Accu Chek blood glucose meter.  The tail was first 
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cleaned with ethanol, and a lancet was used to stick the tip of the tail.  The tail then was 
milked until at least 0.6 microliters of blood was absorbed into the testing strip (Bidasee 
et al., 2008).  In cases where blood glucose exceeded 600 ml/dL the test was repeated.  If 
blood glucose tested higher than 600 mg/dL on the second test, the animal was 
euthanized.  Animals were given free access to food and water for the remainder of the 
study. 
Exercise Training 
Animals in CIT and STZ groups were further divided into the following groups; 
CIT+SED, CIT+TM, STZ+SED, and STZ+TM.  Animals in SED groups were restricted 
to cage activity for 8 weeks.  Animals in TM groups trained five days a week (Monday – 
Friday) for 8 weeks during their dark cycle.  Training speed remained at 18 m/min for the 
entire 8 weeks, while the treadmill incline increased to a maximum of 15% and exercise 
duration reached a maximum of 60 minutes by the end of the training period.  A 
summary of the exercise training regimen appears in Table 1.  
Table 1: Exercise Training Protocol 
Week 1 2 3 4 5 6 7 8 
Speed (m/min) 18 18 18 18 18 18 18 18 
Incline (%) 0 0 0 3 6 9 12 15 
Duration (min) 20 40 60 60 60 60 60 60 
 
Doxorubicin Injection 
Twenty-four hours following the last exercise training session, animals in the 4 
groups were further divided into DOX and SAL for a total of 8 groups (CIT+SED+SAL, 
CIT+SED+DOX, CIT+TM+SAL, CIT+TM+DOX, STZ+SED+SAL, STZ+SED+DOX, 
STZ+TM+SAL, and STZ+TM+DOX).  Doxorubicin was administered as a bolus i.p. 
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injection at a dose of 12.5 mg/kg.  Five days post DOX/SAL injection animals cardiac 
function was assessed using echocardiography and the isolated perfused working heart. 
Echocardiography 
In vivo cardiac function was assessed by echocardiography using a commercially 
available echocardiographic system (Toshiba Nemio 30; 10 MHz transducer).  Animals 
were sedated with ketamine (40 mg/kg, i.p.) and echocardiography was completed within 
10-15 minutes after the administration of the sedative.  From the short-axis view, an M-
mode tracing of the LV was obtained for measures of septal wall thickness during systole 
(SWs) and diastole (SWd), posterior wall thickness during systole (PWs) and diastole 
(PWd), LV end systolic diameter (LVDs), and LV end diastolic diameter (LVDd).  Aortic 
flow was assessed from the five-chamber apical view and mitral flow with a four-
chamber apical view with the smallest possible sample volume placed at the tips of the 
valve.  LV mass was calculated as 1.04[(LVDd + PWd + SWd)3 – LVDd3], relative wall 
thickness (RWT) was calculated as (PWd + SWd)/LVDd, and fractional shortening (FS) 
was calculated as (LVDd – LVDs)/LVDd.   
Isolated Perfused Working Heart 
Following echocardiography, animals were administered heparinized sodium 
pentobarbital (i.p., 50 mg/kg).  Anesthesia was confirmed by the absence of a tail pinch 
reflex, at which time the heart was rapidly excised and immersed in ice-cold Krebs 
Henseleit buffer (120 mM NaCl, 5.9 mM KCl, 2.5 mM CaCl2, 1.2 mM MgCl, 25 mM 
NaHCO3, 17 mM glucose, and 0.5 mM EDTA).  The aorta was cannulated within one 
minute and the heart was subjected to retrograde perfusion with Krebs-Henseleit buffer 
saturated with 95% O2/5% CO2 and temperature was maintained in a water-jacketed 
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column at 37°C for the duration of the experiment.  The pulmonary vein was then 
cannulated and flow was re-directed to enter through the left atrium and exit through the 
aorta to measure cardiac function using the working heart method.  The heart was then 
given 15 minutes to equilibrate before data were collected.  Preload and afterload were 
set at 10 cmH2O and 100 cmH2O above the cannula, respectively.  A microtip catheter 
pressure transducer (Scisense, Ontario, Canada) was inserted into the LV cavity via the 
apex for measurement of end systolic pressure (ESP), end diastolic pressure (EDP), left 
ventricular developed pressure (LVDP), maximum rate of pressure development 
(dP/dtmax) and the minimum rate of pressure development (dP/dtmin). 
Quantification of Cardiac  
Phosphometabolites 
 
Following isolated heart experiments, the left ventricle was isolated, frozen in 
liquid nitrogen, and stored at -80°C for subsequent measurement of ATP, ADP, AMP, 
phosphocreatine, and creatine using high performance liquid chromatography (HPLC).  
Frozen samples were weighed and homogenized immediately with 500 µL cold (4°C) 
perchloric acid (7%).  The homogenate was centrifuged at 8,800g for 5 minutes.  The 
supernatant was extracted and the pH was taken to 7.0 with potassium hydroxide and 
centrifuged again at 8,800g for 5 minutes.  The supernatant was removed and filtered, 
and the pellet was discarded.  The filtered supernatant was injected into a reversed phase 
C-18 column, 15 cm in length with a 5µm particle size and a 3 cm guard.  An isocratic 
mobile phase was used to measure quantities of ATP, ADP, AMP, Cr, and PCr.  The 
running buffer used during the isocratic mobile phase consisted of 215 mM Kh2PO4, 2.3 
mM TBAHS, 3.5% acetonitrile, pH to 6.25 with KOH and filtered through a 2 µm 
cellulose acetate filter.  The spectrophotometer was set at 204 nm with a flow rate of 0.5 
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mL/min.  All phosphometabolites (ATP, ADP, AMP, phosphocreatine, and creatine) 
were eluted from the column within 20 minutes.  
 Prior to sample measurement, standard curves were developed for each of the 
phosphometabolites at 5 different concentrations within a physiological range.  Those 
standard curves were used to determine the μg of phosphometabolite per mg left ventricle 
tissue.  Due to the degree of daily error seen with HPLC, each metabolite quantity was 
then divided by the metabolite quantity of the daily control and reported as a percentage 
of that control.  Sedentary animal samples were controlled with the average of the 
sedentary control samples run that day; exercise trained animal samples were controlled 
with the average of the exercise control samples. 
Statistical Analysis 
Means and standard deviations were calculated for each variable.  A Three-Factor 
Analysis of Variance was used to determine main effects and interaction effects of the 
three treatments, citrate buffer/STZ, sedentary/treadmill, and saline/DOX.  If a significant 
F-value was observed, Tukey post-hoc pairwise comparisons were used to determine 
significance between all treatment combinations (8 groups).  A family alpha level of less 
than 0.05 was considered significant.  
Results 
General Observations 
Of those animals injected with STZ, 31% did not survive the 8 week study.  In 
addition, the success rate of STZ inducing diabetes was 73% of injected animals.  
Survival rates were not different between sedentary and exercise trained animals.  Only 
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two animals (1 sedentary and 1 treadmill trained) were lost following the DOX injection, 
resulting in less than 5% mortality following the DOX injection. 
Main effects testing found that diabetic animals weighed significantly less than 
non-diabetic animals at time of sacrifice, 221 ± 49 grams and 364 ± 55 grams, 
respectively (p<.05).  Diabetic animals’ heart masses were lower than non-diabetic 
animals, 1.0 ± 0.2 grams and 1.4 ± 0.2 grams, respectively (p<.05).  Diabetic animals had 
significantly higher blood glucose levels, 546 ± 45 ml/dL compared to 110 ± 14 ml/dL.  
No significant differences in body mass, heart mass, or blood glucose were seen as a 
result of the exercise training.  Animals in the DOX treatment groups had significantly 
lower body masses compared to saline injected animals, 286 ± 64 grams and 332 ± 101 
grams, respectively (p<.05).  In addition, they had significantly lower heart weights, 1.2 ± 
0.2 grams in the DOX treated groups and 1.3 ± 0.3 grams in the SAL groups (p<.05).  
DOX treated diabetic animals did not have further significant declines in either body or 
heart mass compared to SAL injected diabetic animals.   
Demographic data are displayed in Table 2 and significant differences between 
the 8 groups are indicated.  Groups CIT.SED.SAL (407 ± 43) and CIT.TM.SAL (403 ± 
26) had significantly higher body mass compared to STZ.SED.SAL (223 ±72), 
STZ.TM.SAL (230 ± 32), CIT.SED.DOX (338 ± 44), CIT.TM.DOX (306 ± 26), 
STZ.SED.DOX (204 ± 21), and STZ.TM.DOX (223 ± 47, p <.05, Table 2).  Similarly, 
CIT.SED.SAL (1.6 ± 0.3) and CIT.TM.SAL (1.5 ± 0.1) had significantly higher heart 
mass compared to STZ.SED.SAL (1.1 ± 0.2), STZ.TM.SAL (1.0 ± 0.1), CIT.TM.DOX 
(1.3 ± 0.1), STZ.SED.DOX (1.0 ± 0.1), and STZ.TM.DOX (1.0 ± 0.2, p <.05, Table 2).  
However, the body and heart mass loss was not proportional across all groups, 
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STZ.SED.DOX (0.46 ± 0.02), STZ.TM.DOX (0.45 ± 0.05), and STZ.SED.SAL (0.5 ± 
0.07) had significantly higher relative heart mass compared to both the SED and TM 
controls (p <.05).  As mentioned with the main effects results, all STZ groups had 
significantly higher blood glucose compared to the CIT groups.  Although not significant, 
both CIT.TM.SAL (119 ± 15) and CIT.TM.DOX (113 ± 15) groups had higher blood 
glucose compared to their sedentary counterparts (105 ± 12 and 103 ± 10, respectively).   
Table 2: Subject Demographics 
  N Body Mass (g) Heart Mass (g) Relative Heart Mass (%) Blood Glucose (mL/dL) 
CIT.SAL 
SED 11 407 (43) 1.6 (0.3) 0.38 (0.04) 105 (12) 
TM 14 403 (26) 1.5 (0.1) 0.38 (0.03) 119 (15) 
STZ.SAL 
SED 9 223 (72)*# 1.1 (0.2)*# 0.50 (0.07)*# 543 (70)*# 
TM 7 230 (32)*# 1.0 (0.1)*# 0.44 (0.02) 552 (32)*# 
CIT.DOX 
SED 14 338 (44)*# 1.4 (0.1) 0.41 (0.05) 103 (10) 
TM 11 306 (26)*# 1.3 (0.1)*# 0.42 (0.04) 113 (15) 
STZ.DOX 
SED 8 204 (21)*# 1.0 (0.1)*# 0.49 (0.02)*# 561 (21)*# 
TM 7 223 (47)*# 1.0 (0.2)*# 0.45 (0.05)*# 531 (24)*# 
Data are represented as mean (standard deviation).  CIT = citrate buffer placebo; STZ = 
streptozotocin-induced diabetes; SED = sedentary; TM = treadmill exercise trained; SAL 
= saline placebo; DOX = doxorubicin. Significance level set at p < .05, * compared to 
CIT.SED.SAL, # compared to CIT.TM.SAL 
 
Echocardiography 
Main effects testing resulted in significant changes to the left ventricle were seen 
as the result of STZ-induced diabetes, including decreased LV mass (-35%), as well as 
the left ventricle dimensions SWs (-20%), SWd (-20%), PWs (-23%), PWd (-34%), 
LVDs (-15%), and LVDd (-9%), (p < .05, Table 3).  In addition, calculated variables 
RWT and FS were decreased -31% and -9%, respectively (p<.05), in the STZ groups 
compared to CIT groups (Figure 1).  Exercise training did not have an effect on M-mode 
variables.  Doxorubicin treatment however, resulted in significant declines in LV mass (-
15%), as well as decreased PWs (-8%) and LVDd (-9%), (p<.05, Table 3). 
39 
 


















STZ -0.7* -0.4* -0.8* -0.7* -0.4* -0.2* -328* -0.2* 
TM 0.0 -0.1 0.1 0.1 -0.1 -0.1 -42 0.0 
DOX -0.1 0.0 -0.3* 0.0 -0.1 -0.6* -129* 0.1 
STZ = Streptozotocin-induced diabetes; TM = treadmill exercise trained; DOX = 
doxorubicin; SWs = septal wall thickness at systole; SWd = septal wall thickness at 
diastole; PWs = posterior wall thickness at systole; PWd = posterior wall thickness at 
diastole; LVDs = left ventricular dimension at systole; LVDd = left ventricular dimension 
at diastole; LV mass = left ventricle mass; RWT = relative wall thickness. Data are the 
difference in mean values when subtracted from its control; STZ effect = STZ – CIT; TM 




Figure 1: Fractional Shortening Treatment Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. Fractional 
shortening = (LVDd – LVDs)/LVDd * denotes significance, p <.05. 
 
Table 4 presents the mean and standard deviation of each of the groups on 
analyzed M-mode images.  Septal wall thickness during systole was significantly 
decreased in STZ.SED.SAL (2.8 ± 0.6), STZ.SED.DOX (2.9 ± 0.6), and STZ.TM.DOX 
(2.9 ± 0.6) compared to CIT.SED.SAL (3.8 ± 0.6) and CIT.TM.SAL (3.7 ± 0.5, p<.05).  




± 0.5), STZ.TM.SAL (3.0 ± 0.5), STZ.SED.DOX (2.5 ± 0.5), and STZ.TM.DOX (2.8 ± 
0.4) compared to CIT.SED.SAL (3.8 ± 0.5, p <.05).  Compared to CIT.TM.SAL (3.7 ± 
0.5), STZ.SED.SAL (2.8 ± 0.5), STZ.SED.DOX (2.5 ± 0.5), and STZ.TM.DOX (2.8 ± 
0.4) were significantly decreased (p <.05).  In addition, STZ.SED.DOX (2.5 ± 0.5) was 
significantly decreased compared to CIT.SED.DOX (3.5 ± 0.6) in PWs (p< .05).  Groups 
STZ.SED.SAL (1.4 ± 0.4), STZ.TM.SAL (1.5 ± 0.2), STZ.SED.DOX (1.5 ± 0.3), and 
STZ.TM.DOX (1.5 ± 0.3) had significantly decreased PWd compared to groups 
CIT.SED.SAL (2.2 ± 0.7), CIT.TM.SAL (2.2 ± 0.4), CIT.SED.DOX (2.2 ± 0.6), and 
CIT.TM.DOX (2.2 ± 0.3, p <.05).  No significant differences were seen in LVDs among 
the 8 groups.  LVDd was significantly decreased in the CIT.TM.DOX (5.1 ± 0.8) group 
compared to the CIT.TM.SAL (6.5 ± 1.1) group (p <.05, Table 4). 
Table 4: M-mode Echocardiography 
   SWs SWd PWs PWd LVDs LVDd 
  N M SD M SD M SD M SD M SD M SD 
CIT.SAL 
SED 11 3.8 0.6 2.3 0.5 3.8 0.5 2.2 0.7 2.6 0.7 6.5 1.1 
TM 14 3.7 0.5 2 0.5 3.7 0.5 2.2 0.4 2.5 0.6 6.5 0.6 
STZ.SAL 
SED 9 2.8*# 0.6 1.7 0.3 2.8*# 0.5 1.4*#Ɨǂ 0.4 2.6 0.5 6 0.7 
TM 7 3.1 0.5 1.6* 0.4 3* 0.5 1.5*#Ɨǂ 0.2 2.7 0.9 6.4 0.8 
CIT.DOX 
SED 14 3.7 0.5 2 0.6 3.5 0.6 2.2 0.6 2.2 0.9 5.9 1.2 
TM 11 3.4 0.5 2.1 0.4 3.5 0.4 2.2 0.3 2 0.7 5.1# 0.8 
STZ.DOX 
SED 8 2.9*# 0.6 1.9 0.5 2.5*#Ɨ 0.5 1.5*#Ɨǂ 0.3 2.9 0.7 6.2 1 
TM 7 2.9*# 0.6 1.6 0.3 2.8*# 0.4 1.5*#Ɨǂ 0.3 2.7 0.2 6.1 0.6 
STZ = Streptozotocin-induced diabetes; TM = treadmill exercise trained; DOX = 
doxorubicin; SWs = septal wall thickness at systole; SWd = septal wall thickness at 
diastole; PWs = posterior wall thickness at systole; PWd = posterior wall thickness at 
diastole; LVDs = left ventricular dimension at systole; LVDd = left ventricular dimension 
at diastole; A significance level of p <.05 was set, * compared to CIT.SED.SAL, # 
compared to CIT.TM.SAL, Ɨ compared to CIT.SED.DOX and ǂ compared to 
CIT.TM.DOX 
 
 Table 5 represents the means and standard deviations of the 8 groups.  Left 
ventricle mass was significantly decreased among the following groups, CIT.TM.DOX 
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(743 ± 90), STZ.SED.SAL (553 ± 139), STZ.TM.SAL (632 ± 134), STZ.SED.DOX (658 
± 147), and STZ.TM.DOX (606 ± 154) compared to CIT.SED.SAL (1130 ± 361) and 
CIT.TM.SAL (1011 ± 233, p <.05).  Relative wall thickness was significantly decreased 
in all of the STZ groups compared to CIT.TM.DOX (p <.05).  Although significant as a 
main effect, FS was not significantly different among the 8 treatment groups (Figure 2).  
Cardiac function variables, Vcf, Vcfc, and MPI were not significant among the 8 treatment 
groups.   
Table 5: M-mode Echocardiography 
   LV mass RWT FS Vcf Vcfc MPI 
  N M SD M SD M SD M SD M SD M SD 
CIT.SAL 
SED 11 1130 361 0.73 0.39 0.61 0.07 0.0088 0.0013 0.0007 0.00012 0.4 0.1 
TM 14 1011 233 0.66 0.14 0.62 0.08 0.0089 0.0015 0.00074 0.00013 0.33 0.1 
STZ.SAL 
SED 9 553*# 139 0.52ǂ 0.11 0.57 0.07 0.0067 0.0028 0.00045 0.00022 0.65 0.2 
TM 7 632*# 134 0.5ǂ 0.11 0.59 0.1 0.0088 0.0082 0.00057 0.00039 1.09 2 
CIT.DOX 
SED 14 866 185 0.77 0.34 0.62 0.12 0.047 0.12 0.0033 0.0087 5.02 14.3 
TM 11 743*# 90 0.88 0.24 0.61 0.1 0.0094 0.0023 0.00068 0.00016 0.68 0.3 
STZ.DOX 
SED 8 658*# 147 0.56ǂ 0.15 0.53 0.08 0.0049 0.001 0.00035 0.00008 0.36 0.1 
TM 7 606*# 154 0.52ǂ 0.08 0.56 0.06 0.0058 0.0014 0.00039 0.00011 0.75 0.3 
STZ = Streptozotocin-induced diabetes; TM = treadmill exercise trained; DOX = 
doxorubicin; LV mass = left ventricle mass; RWT = relative wall thickness. A 
significance level of p <.05 was set, * compared to CIT.SED.SAL, # compared to 













Figure 2: Fractional Shortening Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin; FS = 
fractional shortening. 
 
Echocardiography Doppler images were used to analyze HR, maximum blood 
flow through the aortic (Aortic Vmax) and mitral valves (Mitral Vmax), filling time (FT), 
ejection time (ET), isovolumetric relaxation time (IVRT), and isovolumetric contraction 
time (IVCT).  Heart rate was significantly decreased in both STZ and DOX treated 
animals, -23% and -11%, respectively, (p <.05, Table 6).  Exercise training did not have 
an effect on heart rate.  Streptozotocin treatment also resulted in a significant 17% 
decrease in Aortic Vmax compared to controls, (p < .05, Figure 3).  Exercise training 
significantly increased Aortic Vmax by 17% compared to sedentary animals, (p < .05, 
Figure 3).  Ejection time increased by 47% and IVRT increased by 83% with STZ 
treatment, (p < .05, Table 6).  Mitral Vmax was significantly decreased by DOX 





Table 6: Doppler Echocardiography Treatment Main Effects 
 Mitral Vmax (cm/s) FT (ms) Aortic Vmax (cm/s) ET (ms) HRI (ms) IVRT (ms) IVCT (ms) 
STZ -0.5 -2.4 -15.2* 31.5* 50.3* 18.6* 1.2 
TM 4.8 0.6 12.9* -2.5 -7.2 -2.2 0.4 
DOX -16.7* 7.6 -24.4* 0.7 23.3* 5.5 5.1* 
STZ = Streptozotocin-induced diabetes; TM = treadmill exercise trained; DOX = 
doxorubicin; Mitrail Vmax = maximum blood flow through mitral valve; FT = filling time; 
Aortic Vmax = maximum blood flow through aortic valve; ET = ejection time; HRI = 
heart rate interval between beats; IVRT = isovolumetric relaxation time; IVCT = 
isovolmetric contraction time.  Data are the difference in mean values when subtracted 
from its control; STZ effect = STZ – CIT; TM effect = TM – SED; DOX effect = DOX – 
SAL. * denotes significance, p <.05. 
 
 
Figure 3: Aortic Vmax Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. * denotes 










Figure 4: Mitral Vmax Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. * denotes 
significance, p <.05. 
 
Aortic maximal blood flow was significantly decreased in CIT.SED.DOX (64 ± 
27) and STZ.SED.DOX (67 ± 15) compared to CIT.SED.SAL (100 ± 15, Figure 5).  
CIT.TM.DOX (80 ± 11), STZ.TM.SAL (81 ± 12), and STZ.TM.DOX (71 ± 11) were all 
significantly decreased compared to CIT.TM.SAL (109 ± 15, p <.05, Table 7).  Ejection 
time (Table 7) was also significant different among the 8 treatment groups. Group 
CIT.SED.SAL (70 ± 8) ejection time was significantly less that STZ.SED.DOX (108 ± 
13, p <.05).  Group CIT.SED.DOX (59 ± 21) was significantly less than STZ.SED.DOX 
(108 ± 13, p < .05).  Group CIT.TM.DOX (66 ± 10) was significantly less than 
STZ.TM.DOX (101 ± 21, p <.05).  Maximal blood flow through the mitral valve was 
significantly decreased in CIT.SED.DOX (73 ± 19) compared to CIT.SED.SAL (97 ± 17) 
and CIT.TM.DOX (61 ± 11) was significantly decreased compared to CIT.TM.SAL (105 
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± 12, p <.05, Table 7).  Group CIT.TM.DOX (61 ± 11) Mitral Vmax was significantly 
decreased compared to STZ.TM.SAL (92 ± 19, p <.05, Figure 6).  Filling time was not 
significantly different among the 8 treatment groups.  Heart rate was significantly 
decreased in STZ.SED.SAL (257 ± 45) compared to CIT.SED.SAL (378 ± 34).  Groups 
STZ.TM.SAL (282 ± 57) and STZ.TM.DOX (258 ± 62) had significantly decreased heart 
rate compared to CIT.TM.SAL (405 ± 29).  Group STZ.SED.SAL (51 ± 21) had a 
significantly longer IVRT compared to CIT.SED.SAL (18 ± 6, p <.05).  Groups 
STZ.TM.SAL (37 ± 16) and STZ.TM.DOX (47 ± 18) were significantly longer IVRT 
compared to CIT.TM.SAL (15 ± 4, p <.05).  STZ.TM.DOX (25 ± 14) had a significantly 
longer IVCT compared to CIT.TM.SAL (10 ± 4, p <.05).   
 
Table 7: Doppler Echocardiography 
   Mitral Vmax FT Aortic Vmax ET HR IVRT IVCT 
  N M SD M SD M SD M SD M SD M SD M SD 
CIT.SAL 
SED 11 97 17 69 10 100 15 70 8 378 34 18 6 10 4 
TM 14 105* 12 66 8 109 15 70 8 405 29 15 4 8 4 
STZ.SAL 
SED 9 74 18 79 21 76 21 96 30 257* 45 51* 21 13 6 
TM 7 92ǂ 19 74 31 81# 12 88 30 282# 57 37# 16 10 7 
CIT.DOX 
SED 14 73* 19 83 34 64* 27 59 21 308 50 30 7 15 6 
TM 11 61# 11 91 11 80# 11 66 10 312 17 29 13 15 7 
STZ.DOX 
SED 8 92* 12 65 14 67* 15 108*Ɨ 13 285 42 31 10 7 6 
TM 7 84 22 75 35 71# 11 101ǂ 21 258# 62 47# 18 25# 14 
STZ = Streptozotocin-induced diabetes; TM = treadmill exercise trained; DOX = 
doxorubicin; Mitral Vmax = maximum blood flow through mitral valve; FT = filling time; 
Aortic Vmax = maximum blood flow through aortic valve; ET = ejection time; HRI = 
heart rate interval between beats; IVRT = isovolumetric relaxation time; IVCT = 
isovolmetric contraction time.  Data are the difference in mean values when subtracted 
from its control; STZ effect = STZ – CIT; TM effect = TM – SED; DOX effect = DOX – 








Figure 5: Aortic Vmax Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin 
 
 
Figure 6: Mitral Vmax Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 






Isolated Perfused Working Heart 
Ex vivo cardiac function was measured with the isolated perfused working heart 
model.  The main effects treatment with STZ resulted in an increase in ESP (15%), and 
LVPD (16%, p < .05).  Doxorubicin treatment significantly decreased ESP (-15%) and 
LVPD (-18%, p < .05). Treatment with DOX significantly affected dP/dtmax (-16%) and 
dP/dtmin (-14%, p < .05); in addition to increasing EDP (p <.05).  Treadmill training 
positively affected cardiac function measured by an increase in ESP (13%), (p < .05).  
Table 8 contains the treatment effects, while Figures7 and 8 graphically depict the 
treatments’ effects on ESP and LVDP. 
 
Table 8: Isolated Working Heart Treatment Main Effects 
 ESP (mmHg) EDP (mmHg) LVDP (mmHg) dP/dT max (mmHg) dP/dT min (mmHg) HR (bpm) 
STZ 11* 0.0 11* 57 103 -5 
TM 8* 0.4 8 204 138 -6 
DOX -12* 2.5* -14* -496* 363* -2 
STZ = Streptozotocin-induced diabetes; TM = treadmill exercise trained; DOX = 
doxorubicin; ESP = end systolic pressure; EDP = end diastolic pressure; LVDP = left 
ventricular developed pressure; dP/dT max = maximum rate of pressure development; 
dP/dT min = minimum rate of pressure development; HR = heart rate. Data are the 
difference in mean values when subtracted from its control; STZ effect = STZ – CIT; TM 






Figure 7: End Systolic Pressure Treatment Main Effects CIT = citrate buffer placebo; 
STZ = streptozotocin-induced diabetes; SED = sedentary; TM = treadmill exercise 





Figure 8: Left Ventricular Developed Pressure Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. * denotes 




 Table 9 displays the means and standard deviations from ex vivo cardiac 
assessment of the 8 treatment groups.  Statistically, there were no meaningful differences 
between the 8 treatment groups.  However, trends are observed and will be discussed in 




Table 9: Isolated Working Heart 
   ESP (mmHg) EDP (mmHg) LVDP (mmHg) dP/dtmax (mmHg/s) dP/dtmin (mmHg/s) HR (bpm) 
  N M SD M SD M SD M SD M SD M SD 
CIT.SAL 
SED 11 76 22 -0.6 1.7 76 23 3210 771 -2585 436 122 34 
TM 14 76 16 -3 10 79 24 3294 785 -3019 1344 114 29 
STZ.SAL 
SED 9 73 22 -0.7 0.9 74 22 2927 630 -2651 1060 103 59 
TM 7 89 16 0.9 1.8 88 17 3017 549 -2334 261 106 27 
CIT.DOX 
SED 14 55 13 1.2 2.8 54 12 2426 418 -2301 487 115 48 
TM 11 66 13 3 3.9 63 16 2589 357 -2304 261 100 35 
STZ.DOX 
SED 8 73 21 -0.7 1.1 73 21 2698 660 -2270 179 114 36 
TM 7 80 9 1.4 3.6 79 9 3032 503 -2502 615 108 62 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; TM = treadmill exercise trained; SAL = saline 
placebo; DOX = doxorubicin ESP = end systolic pressure; EDP = end diastolic pressure; LVDP = left ventricular developed pressure; 









Figure 9: End Systolic Pressure Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 





Figure 10: Left Ventricular Developed Pressure Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 





Quantification of Cardiac  
Phosphometabolites 
 
With main effects testing, all phosphometabolites were significantly increased 
after treadmill exercise training (Figures 11-15).  Exercise training increased ATP content 
in STZ treated animals by 27% and 20% in those treated with DOX, (p < .05).  Exercise 
training increased Cr levels in STZ and DOX treated groups by 62% and 47%, 
respectively, (p < .05).  Although no effect is seen in DOX treated groups, exercise 
training increased PCr levels in STZ treated animals by 32%, (p < .05).  Exercise training 
increased ADP levels in DOX treated animals significantly by 15%, (p < .05); while 
significant increases in AMP with exercise training were only seen in STZ treated 
animals (64%, p < .05).  Apart from the main effect of exercise, there were no new 
findings when comparing all 8 groups; Figures 16-20 graph the group means and 
standard deviations. 
 
Figure 11: ATP Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. ATP was 
quantified as % of daily control sample quantity to control for instrument error. * denotes 





Figure 12: Creatine Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. Cr was 
quantified as % of daily control sample quantity to control for instrument error. * denotes 




Figure 13: Phosphocreatine Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. PCr was 
quantified as % of daily control sample quantity to control for instrument error. * denotes 








Figure 14: ADP Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. ADP was 
quantified as % of daily control sample quantity to control for instrument error. * denotes 





Figure 15: AMP Treatment Main Effects 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. AMP was 
quantified as % of daily control sample quantity to control for instrument error. * denotes 






Figure 16: ATP Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. ATP was 




Figure 17: Creatine Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. Cr was 








Figure 18: Phosphocreatine Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. PCr was 







Figure 19: ADP Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. ADP was 







Figure 20: AMP Group Comparisons 
CIT = citrate buffer placebo; STZ = streptozotocin-induced diabetes; SED = sedentary; 
TM = treadmill exercise trained; SAL = saline placebo; DOX = doxorubicin. AMP was 




The present study demonstrated the adverse cardiovascular effects of DOX and 
STZ treatments, individually and in combination.  Additionally, exercise training was 
able to attenuate the cardiac dysfunction induced by DOX and STZ, individually and in 
combination.  Furthermore, exercise training significantly increased cardiac 
phosphometabolite levels in the left ventricle. 
Body and heart masses were significantly decreased with the treatment of STZ 
and DOX; however, the relative heart mass was increased in animals treated with STZ or 
the combination of STZ and DOX.  Diabetes has been shown to increase blood viscosity 






In the present study, diabetes resulted in decreased left ventricle dimensions 
during both systole and diastole, left ventricle mass, relative wall thickness, and 
fractional shortening.  Dysfunction was also observed in STZ animals with maximum 
aortic blood flow and ejection time.  Previous studies have found after as little as 5 weeks 
of STZ-induced diabetes that left ventricle dimensions are decreased during both diastole 
and systole, along with decreased fractional shortening and peak blood flow velocities 
(Joffe et al., 1999).  In addition, DOX treatment lead to significant declines in left 
ventricle dimensions, and left ventricle mass.  The ex vivo analysis of cardiac function, 
revealed significant dysfunction measured by decreases in ESP and LVDP with DOX 
treatment.  Streptozotocin treatment resulted in an increase in ESP and LVDP, which 
could be the result of the absence of fatty acids in the perfused buffer.  Increases in 
plasma concentration of fatty acids, fatty acid transporters, and fatty acid uptake appear 
to be large components in the shift to increased fatty acid utilization seen in diabetics.  
Fatty acid oxidation typically provides 60 – 70% of the heart’s energy needs (Neeley & 
Morgan, 1974); however, in the uncontrolled diabetic heart, that percentage increases to 
90 – 100% (Lopaschuk, 1996).  By perfusing hearts with lipid-free buffer, studies have 
found that the diabetic heart increases its utilization of glucose from 0-10% to 20% of its 
energy requirements (Lopachuk, 1996).  Therefore, the unexpected increase in ESP and 
LVDP, could be the result of a buffer inconsistent with the diabetic condition.  In 
addition, function could have improved due to the improvement in blood viscosity, 
especially if the heart had experienced hypertensive hypertrophy.  The interaction of STZ 
and DOX on LVSP and ESP has shown that the effect of STZ treatment is exacerbated by 
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treatment with DOX.  One study found that diabetic patients receiving DOX had an 
increased likelihood of congestive heart failure (Hershman, McBride, Eisenberger, Tasi, 
Grann, & Jacobson, 2008). 
Cardiac Metabolic Dysfunction 
The current study did not find altered phosphometabolite content in the left 
ventricle following treatment with STZ or DOX treatment.  Previous research found that 
ATP synthesis is slowed in diabetic animals, concluded by increased levels of ADP and 
AMP, however, no significant decline in ATP availability was seen in diabetic cardiac 
tissue (Ferko, M., Gvozdjakova, A., Kucharska, J., Mujkosova, J., Waczulikova, I., Styk, 
J., et al., 2006).  Contrary to the present findings, DOX-induced cardiotoxicity has been 
found to significantly decrease myocardial ATP, along with decreases in creatine, 
phosphocreatine and lactate, indicating both aerobic and anaerobic metabolic dysfunction 
(Wallace, 2003).  Although STZ and DOX did not significantly affect phosphometabolite 
content, the effect of exercise to increase phosphometabolites was present across all 
treatments.  Exercise significantly increased ATP and Cr in animals treated with STZ and 
DOX and may partially explain the benefits of exercise training on cardiac function in 
STZ and DOX treated animals. 
Exercise Cardioprotecion 
Exercise attenuated cardiac dysfunction induced by STZ and DOX treatments, 
and in the cases of aortic blood flow and end systolic pressure, had a significant effect 
over all sedentary groups.  Bidasee and colleagues (2008) investigated the effects of 
exercise training on cardiac function in STZ-induced diabetic rats.  It was found that 
following seven weeks of diabetes, rats had decreased heart rates, fractional shortening, 
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and ejection fraction.  Three weeks of treadmill training was able to improve ejection 
fraction.  A similar study using STZ-induced diabetic rats found that after nine weeks of 
treadmill training and seven weeks of STZ-induced diabetes exercise was found to 
significantly attenuate the magnitude of mitochondrial ultrastructure damage, assessed 
using transmission electron microscopy (Searls et al., 2004). 
The use of exercise to attenuate DOX-induced cardiotoxicity has been 
demonstrated across different modes of exercise, intensities, and durations (Ascensao et 
al., 2005, Chicco et al., 2005, Chicco et al., 2006 and Wonders et al., 2008).  All have 
identified exercise as a means of attenuating cardiotoxicity through preserved cardiac 
function, decreased apoptosis, decreased oxidative stress, increased antioxidant capacity, 
and improved calcium homeostasis (Ascensao et al. 2005, Ascensao et al., 2006, Chicco, 
et al., 2005, Chicco et al., 2006, Hydock et al., 2011, and Wonders et al., 2009).   
Exercise training resulted in an increase in all phosphometabolites, and those 
increases were seen in animals treated with STZ and DOX.  Exercise increases both 
glucose and fatty acid utilization and thus increases available ATP.  Exercise leads to an 
increase in AMPK, which in turn inactivates ACC and malonyl CoA, thereby increasing 
fatty acid oxidation, in addition, AMPK also stimulates glucose uptake (through insulin, 
which may not be present in STZ diabetic hearts) and glycolysis by activating PFK.  Thus 








 Exercise training protects against STZ and DOX –induced cardiac dysfunction.  
In addition, exercise training significantly increased the availability of 
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Blood Glucose Data 
 Week 0 1 2 3 4 5 6 7 8 
CIT.SED.SAL M 102 105 103 105 109 106 101 90 96 
SD 11 14 14 14 12 10 8 10 10 
CIT.SED.DOX M 102 105 101 99 106 102 97 103 98 
SD 12 13 14 11 14 15 10 12 14 
CIT.TM.SAL M 97 117 125 114 111 144 123 113 106 
SD 8 18 33 18 14 49 37 12 9 
CIT.TM.DOX M 98 99 112 112 106 119 128 114 110 
SD 8 12 17 15 13 27 40 16 13 
STZ.SED.SAL M 102 347 516 557 581 584 578 587 589 
SD 11 195 130 77 49 55 71 30 20 
STZ.SED.DOX M 108 382 512 600 587 600 600 600 599 
SD 5 118 55 0 28 0 0 0 3 
STZ.TM.SAL M 98 208 564 587 600 586 600 600 597 
SD 11 164 67 18 0 35 0 0 7 
STZ.TM.DOX M 101 268 551 566 599 593 600 600 600 











METABOLITE STANDARD CURVES  





























Prior to running hypothesis testing, assumptions were tested.  Independence was 
not violated, as the occurrence of one event does not affect the probability of another 
event.  Normal distribution was confirmed with a Shapiro-Wilk test (p >.05), normal 
probability plots were also used to assess the sample distribution.  Residual box plots and 
Levene’s test were used to assess the equality of variance; both concluded the data have 
















A pilot study consisting of 25 animals, both males and females was conducted to 
determine feasibility and to assess the degree of cardiac dysfunction that might be 
expected with combined STZ-DOX treatment.  A group (12 animals) received an STZ 
injection of 65 mg/kg.  All animals in this group weighed between 190 and 215 grams at 
the time of injection.  Eleven of the 12 animals had confirmed diabetes three days post 
injection.  Those with confirmed diabetes maintained very high blood glucose levels 
around 600 mg/dL for 10 weeks.  Four of the 12 animals died during the 10 week study.  
The average body weight at the end of the 10 weeks was 143 grams for diabetic animals 
treated with 65 mg/kg STZ.  Cardiac function was measured with the isolated working 
heart model.  A second group of 12 animals received an STZ injection of 45 mg/kg.  
These animals weighed between 200 and 280 grams at the time of STZ injection.  Of the 
12 injected with STZ, 10 had confirmed diabetes 3 days following, and no deaths 
occurred as a result of STZ exposure.  Seven animals in this group were injected with 10 
mg/kg of DOX after 10 weeks of being diabetic.  One of the STZ + DOX animals died 
prior to analysis.  In vivo and ex vivo measures were used to assess cardiac function.  
Table 3 and Figures 3- 6 summarized the findings of this pilot study.  Significance was 
determined by one-way ANOVA analyses.  These pilot studies indicated that in our 
laboratory, STZ at 45 mg/kg STZ showed elevated blood glucose, but blood glucose did 
not exceed the euthanization cutoff value of 600 mg/dL in any animal at any time.  
Furthermore, these studies clearly established that in sedentary animals STZ alone and 
DOX alone cause significant cardiac dysfunction, and the combination of STZ and DOX 
exacerbated cardiac dysfunction.  From these pilot studies, it appears that this will be an 
appropriate model to answer the proposed research questions. 
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Success Rate 92% 83% ------------- 
Mortality 
Rate 
33% 0% 14% 
Table 3: Calculated success and mortality rates 
 
 
Figure 3: Average blood glucose levels measured throughout the 10 weeks, grouped by 



























Figure 4: Left ventricular developed pressure. * significant difference compared to SAL 



































Figure 5: End systolic pressure. * significant difference compared to SAL + SAL; • 
significant difference compared to SAL+DOX 
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Figure 6: Fractional Shortening. * significant difference compared to SAL + SAL; • 
significant difference compared to SAL+DOX 
 
